Evidence map›Paper›PMID 35865750›Full record

ArticleFrontiers in aging neuroscience2022

The Natural History of Spinocerebellar Ataxia Type 3 in Mainland China: A 2-Year Cohort Study.

Yun Peng, Linliu Peng, Zhao Chen, Huirong Peng, Puzhi Wang, Youming Zhang, Yangping Li, Chunrong Wang, Yuting Shi, Xuan Hou and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in aging neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Yun PengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Linliu PengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Zhao ChenDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Huirong PengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Puzhi WangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Youming ZhangDepartment of Radiology, Xiangya Hospital, Central South University, Changsha, China.
Yangping LiDepartment of Human Genetics, Emory University School of Medicine, Atlanta, GA, United States.
Chunrong WangDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Yuting ShiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Xuan HouDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Zhe LongDepartment of Neurology, The Second Xiangya Hospital, Central South University, Changsha, China.
Hongyu YuanDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Na WanDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Linlin WanDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Keqin XuDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Lijing LeiDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Shang WangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Lang HeDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Yue XieDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Yiqing GongDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Qi DengDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Guangdong ZouDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Zhichao TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Lu ShenDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Kun XiaLaboratory of Medical Genetics, Central South University, Changsha, Hunan, China.
Rong QiuSchool of Computer Science and Engineering, Central South University, Changsha, China.
Thomas KlockgetherDepartment of Neurology, University of Bonn, Bonn, Germany.
Beisha TangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Hong JiangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The natural history of spinocerebellar ataxia type 3 (SCA3) has been reported in several populations and shows heterogeneity in progression rate and affecting factors. However, it remains unexplored in the population of Mainland China. This study aimed to identify the disease progression rate and its potential affecting factors in patients with SCA3 in Mainland China. Participants and Methods: We enrolled patients with genetically confirmed SCA3 in Mainland China. Patients were seen at three visits, i.e., baseline, 1 year, and 2 years. The primary outcome was the Scale for the Assessment and Rating of Ataxia (SARA), and the secondary outcomes were the Inventory of Non-Ataxia Signs (INAS) as well as the SCA Functional Index (SCAFI). Results: Between 1 October 2015, and 30 September 2016, we enrolled 263 patients with SCA3. We analyzed 247 patients with at least one follow-up visit. The annual progression rate of SARA was 1.49 points per year (SE 0.08, 95% confidence interval [CI] 1.33-1.65, Conclusion: Our results provide quantitative data on the disease progression of patients with SCA3 in Mainland China and its corresponding affecting factors, which could facilitate the sample size calculation and patient stratification in future clinical trials. Trial Registration: This study was registered with Chictr.org on 15 September 2015, number ChiCTR-OOC-15007124.

Indexed as

ATXN3disease progressionMachado-Joseph disease (MJD)natural historyspinocerebellar ataxia type 3

Identifiers

PMID35865750
PMCPMC9294347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.